Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017.

Date publication

janvier 2024

Journal

Journal of cancer research and clinical oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Reitmajer M, Leiter U, Nanz L, Amaral T, Flatz L, Garbe C, Forschner A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38238578

Résumé

Since the introduction of immune checkpoint inhibitors (ICI) and targeted therapies (TT), survival rates of metastatic melanoma patients have increased significantly and complete remissions are no longer rarities. Consequently, there is an increasing number of long-term survivors who have not yet been comprehensively characterized.

Mots clés

Immune checkpoint inhibitor (ICI), Long-term survivors, Melanoma stage IV, Survivorship, Targeted therapy (TT)

Référence

J Cancer Res Clin Oncol. 2024 01 18;150(1):15